216 related articles for article (PubMed ID: 33178361)
1.
Li B; Huang H; Huang R; Zhang W; Zhou G; Wu Z; Lv C; Han X; Jiang L; Li Y; Li B; Zhang Z
Dis Markers; 2020; 2020():6289063. PubMed ID: 33178361
[TBL] [Abstract][Full Text] [Related]
2. Plasma mSEPT9: A Novel Circulating Cell-free DNA-Based Epigenetic Biomarker to Diagnose Hepatocellular Carcinoma.
Oussalah A; Rischer S; Bensenane M; Conroy G; Filhine-Tresarrieu P; Debard R; Forest-Tramoy D; Josse T; Reinicke D; Garcia M; Luc A; Baumann C; Ayav A; Laurent V; Hollenbach M; Ripoll C; Guéant-Rodriguez RM; Namour F; Zipprich A; Fleischhacker M; Bronowicki JP; Guéant JL
EBioMedicine; 2018 Apr; 30():138-147. PubMed ID: 29627389
[TBL] [Abstract][Full Text] [Related]
3. Plasma levels of methylated septin 9 are capable of detecting hepatocellular carcinoma and hepatic cirrhosis.
He N; Feng G; Zhang C; Wu F; Zhang T; Yang Y
Mol Med Rep; 2020 Oct; 22(4):2705-2714. PubMed ID: 32945374
[TBL] [Abstract][Full Text] [Related]
4. Role of methylated septin 9 as an adjunct diagnostic and prognostic biomarker in hepatocellular carcinoma.
Bannaga AS; Alvarez R; Zhou L; Petchey M; Noufaily A; Hitchins MP; Arasaradnam RP
HPB (Oxford); 2021 Oct; 23(10):1595-1606. PubMed ID: 33931320
[TBL] [Abstract][Full Text] [Related]
5. Methylated SEPT9 combined with AFP and PIVKA-II is effective for the detection of HCC in high-risk population.
Zheng K; Dai L; Zhao Y; Li L; Li W; Zhang X; Su Q; Wu R; Jiang Y; Chen Y; Ran J
BMC Gastroenterol; 2023 Jul; 23(1):260. PubMed ID: 37525116
[TBL] [Abstract][Full Text] [Related]
6. [Expression and clinical significance of plasma methylated SEPT 9 gene in patients with primary liver cancer].
He N; Feng G; Zhang FN; Hao S; Li R; Zhao ZQ; Tian YW; Yan HL
Zhonghua Gan Zang Bing Za Zhi; 2023 Mar; 31(3):265-270. PubMed ID: 37137852
[No Abstract] [Full Text] [Related]
7. A Circulating Long Noncoding RNA Panel Serves as a Diagnostic Marker for Hepatocellular Carcinoma.
Huang J; Zheng Y; Xiao X; Liu C; Lin J; Zheng S; Yang B; Ou Q
Dis Markers; 2020; 2020():5417598. PubMed ID: 32733618
[TBL] [Abstract][Full Text] [Related]
8. Cell-free methylation markers with diagnostic and prognostic potential in hepatocellular carcinoma.
Lu CY; Chen SY; Peng HL; Kan PY; Chang WC; Yen CJ
Oncotarget; 2017 Jan; 8(4):6406-6418. PubMed ID: 28031532
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP.
Choi JY; Jung SW; Kim HY; Kim M; Kim Y; Kim DG; Oh EJ
World J Gastroenterol; 2013 Jan; 19(3):339-46. PubMed ID: 23372355
[TBL] [Abstract][Full Text] [Related]
10. Development and application of a fluorescence protein microarray for detecting serum alpha-fetoprotein in patients with hepatocellular carcinoma.
Zhang A; Yin C; Wang Z; Zhang Y; Zhao Y; Li A; Sun H; Lin D; Li N
J Int Med Res; 2016 Dec; 44(6):1414-1423. PubMed ID: 27885040
[TBL] [Abstract][Full Text] [Related]
11. Hypomethylation of the cyclin D1 promoter in hepatitis B virus-associated hepatocellular carcinoma.
Liu HH; Fang Y; Wang JW; Yuan XD; Fan YC; Gao S; Han LY; Wang K
Medicine (Baltimore); 2020 May; 99(20):e20326. PubMed ID: 32443384
[TBL] [Abstract][Full Text] [Related]
12. PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma.
Feng H; Li B; Li Z; Wei Q; Ren L
BMC Cancer; 2021 Apr; 21(1):401. PubMed ID: 33849479
[TBL] [Abstract][Full Text] [Related]
13. Combination of miR-125b and miR-27a enhances sensitivity and specificity of AFP-based diagnosis of hepatocellular carcinoma.
Zuo D; Chen L; Liu X; Wang X; Xi Q; Luo Y; Zhang N; Guo H
Tumour Biol; 2016 May; 37(5):6539-49. PubMed ID: 26637228
[TBL] [Abstract][Full Text] [Related]
14. Role of Plasma methylated SEPT9 for Predicting Microvascular Invasion and Tumor Proliferation in Hepatocellular Carcinoma.
Huang F; Yang G; Jiang H; Chen X; Yang Y; Yu Q; Pan B; Wang B; Guo W; Yang W; Zhang C
Technol Cancer Res Treat; 2022; 21():15330338221144510. PubMed ID: 36573042
[No Abstract] [Full Text] [Related]
15. Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients.
Lim TS; Kim DY; Han KH; Kim HS; Shin SH; Jung KS; Kim BK; Kim SU; Park JY; Ahn SH
Scand J Gastroenterol; 2016 Mar; 51(3):344-53. PubMed ID: 26340708
[TBL] [Abstract][Full Text] [Related]
16. Serum miR-224 as a biomarker for detection of hepatocellular carcinoma at early stage.
Lin L; Lu B; Yu J; Liu W; Zhou A
Clin Res Hepatol Gastroenterol; 2016 Sep; 40(4):397-404. PubMed ID: 26724963
[TBL] [Abstract][Full Text] [Related]
17. Role of ssDNA as a Noninvasive Indicator for the Diagnosis and Prognosis of Hepatocellular Carcinoma: An Exploratory Study.
Zhao Q; Xu Y; Yuan D; Yang J; Wang Y; Shen G; Huang X
Dis Markers; 2021; 2021():9958909. PubMed ID: 34394775
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic value of 5 serum biomarkers for hepatocellular carcinoma with different epidemiological backgrounds: A large-scale, retrospective study.
Liu D; Luo Y; Chen L; Chen L; Zuo D; Li Y; Zhang X; Wu J; Xi Q; Li G; Qi L; Yue X; Zhang X; Sun Z; Zhang N; Song T; Lu W; Guo H
Cancer Biol Med; 2021 Feb; 18(1):256-270. PubMed ID: 33628599
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of prothrombin induced by vitamin K absence, macrophage migration inhibitory factor and Golgi protein-73 versus alpha fetoprotein for hepatocellular carcinoma diagnosis and surveillance.
Ismail MM; Morsi HK; Abdulateef NA; Noaman MK; Abou El-Ella GA
Scand J Clin Lab Invest; 2017 May; 77(3):175-183. PubMed ID: 28276727
[TBL] [Abstract][Full Text] [Related]
20. Plasma SGIP1 methylation in diagnosis and prognosis prediction in hepatocellular carcinoma.
Xie GF; Xu YX; Xu F; Sun LY; Ye ZL; Ma JJ; Wang HY; Shao JY
Neoplasma; 2021 Jan; 68(1):62-70. PubMed ID: 33118832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
